Abstract:ABSTRACT Objective Development of obesity and type-2-diabetes (T2D) are associated with gut microbiota (GM) changes. The gut viral community is predominated by bacteriophages (phages), which are viruses that attack bacteria in a host-specific manner. As a proof-of-concept we demonstrate the efficacy of faecal virome transplantation (FVT) from lean donors for shifting the phenotype of obese mice into closer resemblance of lean mice. Design The FVT consisted of viromes extracted from the caecal content of mice fed a low-fat (LF) diet for fourteen weeks. Male C57BL/6NTac mice were divided into five groups: LF (as control), high-fat diet (HF), HF+Ampicillin (Amp), HF+Amp+FVT and HF+FVT. At week six and seven of the study the HF+FVT and HF+Amp+FVT mice were treated with FVT by oral gavage. The Amp groups were treated with ampicillin 24 h prior to first FVT treatment. Results Six weeks after first FVT the HF+FVT mice showed a significant decrease in weight gain compared to the HF group. Further, glucose tolerance was comparable between the lean LF and HF+FVT mice, while the other HF groups all had impaired glucose tolerance. These observations were supported by significant shifts in GM composition, blood plasma metabolome, and expression levels of genes involved in obesity and T2D development. Conclusions Transfer of gut viral communities from mice with a lean phenotype into those with an obese phenotype reduce weight gain and normalise blood glucose parameters relative to lean mice. We hypothesise that this effect is mediated via FVT-induced GM changes. Significance of this study What is already known about this subject? Obesity and type-2-diabetes (T2D) are associated with gut microbiota (GM) dysbiosis. Faecal microbiota transplant from lean donors has previously shown potential in treating obesity and T2D. Patients suffering from recurrent Clostridium difficile infections (rCDI) have been cured with sterile filtered donor faeces (containing enteric viruses and no bacteria), here defined as faecal virome transplantation (FVT). What are the new findings? FVT from lean donors lead to decreased weight gain and normalised blood sugar tolerance in a diet-induced obesity (DIO) mouse model. FVT significantly changed the bacterial and viral GM component, as well as the plasma metabolome and the expression profiles of obesity and T2D associated genes. Initial treatment with ampicillin prior FVT seems to counteract the beneficial effects associated with FVT. How might it impact on clinical practice in the foreseeable future? We here show a proof-of-concept, providing a solid base for designing a clinical study of FVT targeting obesity and T2D in humans. This is further augmented by the increased safety related to FVT, since bacteria and other microorganisms are removed from the donor faeces, and therefore minimises the risk of disease transmission. These findings highlight the potential application of FVT treatment of various diseases related to GM dysbiosis and further support the vital role of the viral community in maintaining and shaping the GM.

Fecal virome transfer improves proliferation of commensal gut Akkermansia muciniphila and unexpectedly enhances the fertility rate in laboratory mice

Akkermansia and the microbial metabolites butyric acid and deoxycholic acid play key roles in fecal microbiota transplantation for the treatment of campylobacteriosis in mice

Fecal Virome Transplantation (FVT) from healthy humans remodels the gut bacteriome and virome and reduces metabolic syndrome in mice

Transfer of modified gut viromes improves symptoms associated with metabolic syndrome in obese male mice

Faecal virome transplantation decrease symptoms of type-2-diabetes and obesity in a murine model

Faecal virome transplantation decreases symptoms of type 2 diabetes and obesity in a murine model

Transfer of modified fecal viromes improve blood glucose regulation and alleviates symptoms of metabolic dysfunction-associated fatty liver disease in an obesity male mouse model

Autochthonous faecal viral transfer (FVT) impacts the murine microbiome after antibiotic perturbation

Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments

Fecal virome transplantation is sufficient to alter fecal microbiota and drive lean and obese body phenotypes in mice

Improvement in sperm quality and spermatogenesis following faecal microbiota transplantation from alginate oligosaccharide dosed mice

Chemostat culturing reduces fecal eukaryotic virus load and delays diarrhea after virome transplantation

Rescue of male fertility following faecal microbiota transplantation from alginate oligosaccharide-dosed mice

Fecal virus transplantation has more moderate effect than fecal microbiota transplantation on changing gut microbial structure in broiler chickens

Human vaginal microbiota colonization is regulated by female sex hormones in a mouse model

Probiotic treatment with specific lactobacilli does not improve an unfavorable vaginal microbiota prior to fertility treatment-A randomized, double-blinded, placebo-controlled trial

Effect of Probiotics on Sperm Quality in the Adult Mouse

In vitro ruminal fermentation and cow-to-mouse fecal transplantations verify the inter-relationship of microbiome and metabolome biomarkers: potential to promote health in dairy cows

Stable core virome despite variable microbiome after fecal transfer

Improvement in Ovarian Function Following Fecal Microbiota Transplantation from High-Laying Rate Breeders

Bacteriophage-mediated manipulation of the gut microbiome - promises and presents limitations